

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Complete if Known

Application Number	10/565,068
Filing Date	July 13, 2006
First Named Inventor	Parry John Guilford
Art Unit	1643
Examiner Name	Alana Harris
Attorney Docket Number	PEBL-01006US1

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.†	Foreign Patent Document Country Code* Number* Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
	1	WO 2001/94629	12-13-2001	Young	
	2	WO 1998/41864	09-24-1998	Ristimäki	

Examiner
SignatureDate
Considered

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Indicate copy of this form with communication to applicant. ¹ Applicant's unique citation designation (if optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/565,068
		Filing Date	July 13, 2006
		First Named Inventor	Parry John Guilford
		Art Unit	1643
		Examiner Name	Alana Harris
Sheet 2 of 3	Attorney Docket Number	PEBL-01006US1	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	European Examination Report dated Oct. 6, 2010 in Application No. 04778461.6 - 1222 / 1649064	
	2	DEZWART, LOECKIE, L., Biomarkers of free radical damage applications in experimental animals and in humans, Free Radical Biology & Medicine, Vol. 26, Nos. 1/2, pp. 202-226, 1999	
	3	SALMELA, MT, Parallel expression of macrophage metalloelastase (MMP-12) In duodenal and skin lesions and patients with dermatitis herpetiformis, GUT online, Gut2001;48;496-502	
	3	13 April 2008	
	4	FINLAY, MARTIN BJ, Prostate Cancer Prostatic Dis. 2004 Mar 9, PubMed, Louisiana University Health Sciences Center, New Orleans, LA.	
	5	Japanese Office Action translation.	
	6	YOSHIKAWA, TAKAKI, Prognostic value of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with gastric cancer, Elsevier, Cancer Letters 151 (2000) 81-86	
	7	RUDLAND, PHILIP S., Prognostic Significance of the Metastasis-associated Protein Osteopontin in Human Breast Cancer, Cancer Research 62, 3417-3427, June 15, 2002	
	8	Taiwanese Office Action, translation	
	9	BUCKHAULTS, PHILLIP, Secreted and cell surface genes expressed in benign and malignant colorectal tumors, Cancer Research 61, 6996-7001, October 1, 2001	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.96. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/565,068
Filing Date	July 13, 2006
First Named Inventor	Parry John Guilford
Art Unit	1643
Examiner Name	Alana Harris
Attorney Docket Number	PEBL-01006US1

Sheet 3 of 3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	10	HOTTE, SEBASTIAN J., Plasma Osteopontin, 2002, American Cancer Society	
	11	KIM, JAE-HOON, Osteopontin as a potential diagnostic biomarker for ovarian cancer, JAMA, American Medical Association, April 3, 2002, Vol. 287, No. 13. 1671-1682.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.